ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lenvatinib

Also written as “Lenvatinib”, “E7080” and “HOPE”.

Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.

Drug pageLenvatinib: every studyAll 431 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 19, 201879 company-led studies, 3 open or runningNext primary completion: Oct 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only511 open or runningphase 4since Jun 19, 2018Jul 15, 2005none ahead
Merck261 open or runningphase 3since Jan 22, 2019Aug 3, 2016Oct 22, 2027phase 2 · NCT02861573
AGO Researchits history only11 open or runningphase 2since May 11, 2023May 11, 2023Oct 30, 2027phase 2 · NCT05903833
Merck KGaA, Darmstadt, Germanyits history only10 open or runningphase 1since Oct 4, 2021Oct 4, 2021none ahead

Also a collaborator on its studies: Ono Pharmaceutical, PharmaBio Development and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Aug 3, 2016.

  1. Dec 12, 2019Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT04199104 · 511 enrolled · United States, Australia, Brazil and more
  2. Jan 27, 2020Phase 3 study in Carcinoma, HepatocellularNCT04246177 · 480 enrolled · United States, Australia, Brazil and more
  3. Mar 9, 20202 phase 2 studies in MelanomaNCT04305054, NCT04305041
  4. Jun 9, 20202 phase 2 studiesNCT04428151, NCT04447755
  5. Dec 4, 20202 phase 3 studiesNCT04662710, NCT04676412
  6. Jan 7, 2021Phase 2 study in Carcinoma, Renal CellNCT04704219 · 160 enrolled · United States, Australia, Canada and more
  7. Jan 19, 2021Phase 3 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT04716933 · 201 enrolled · China
  8. Feb 26, 2021Phase 3 study in Colorectal NeoplasmsNCT04776148 · 563 enrolled · United States, Argentina, Australia and more
  9. Apr 26, 2021Phase 3 study in Endometrial NeoplasmsNCT04865289 · 130 enrolled · China
  10. May 12, 2021Phase 3 study in MelanomaNCT04889118 · 131 enrolled · China
  11. Jun 9, 2021Phase 2 study in Small Cell Lung CarcinomaNCT04924101 · 122 enrolled · United States, Austria, Canada and more
  12. Jun 29, 2021Phase 3 study in Esophageal Squamous Cell CarcinomaNCT04949256 · 863 enrolled · United States, Argentina, Canada and more
  13. Aug 29, 2022Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT05523323 · 112 enrolled · China
  14. Nov 18, 2026Phase 2 study terminatedStudy stoppedNCT04428151 · “Business Reasons”

Ahead

  1. Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT02861573

TargetBeta

“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
AxitinibrulePfizerphase 345
chiauranibruleChipscreen Biosciencesphase 315

Studies

All 26 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05523323Squamous Cell Carcinoma of Head and Neck · China3CompletedAug 25, 2023112
NCT04949256Esophageal Squamous Cell Carcinoma · United States, Argentina, Canada and more3TerminatedMay 8, 2025863
NCT04924101Small Cell Lung Carcinoma · United States, Austria, Canada and more2CompletedJun 23, 2025122
NCT04889118Melanoma · China3CompletedJan 18, 2023131
NCT04865289Endometrial Neoplasms · China3CompletedOct 2, 2023130
NCT04776148Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedSep 27, 2024563
NCT04716933Parkinson Disease 4, Autosomal Dominant Lewy Body · China3CompletedAug 11, 2023201
NCT04704219Carcinoma, Renal Cell · United States, Australia, Canada and more2CompletedJan 27, 2025160
NCT04676412Carcinoma, Non-Small-Cell Lung · China3CompletedMay 19, 2021107
NCT04662710Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedOct 29, 2024895
NCT04447755Recurrence · United States, Argentina, Australia and more2CompletedSep 16, 2022127
NCT04428151Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more2TerminatedMay 31, 2024408
NCT04305054Melanoma · United States, Argentina, Australia and more2CompletedMay 18, 2026335
NCT04305041Melanoma · United States, Australia, France and more2CompletedAug 25, 2025100
NCT04246177Carcinoma, Hepatocellular · United States, Australia, Brazil and more3TerminatedAug 19, 2025480
NCT04199104Squamous Cell Carcinoma of Head and Neck · United States, Australia, Brazil and more3CompletedMay 30, 2023511
NCT03976375Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedAug 11, 2023422
NCT03898180Carcinoma, Transitional Cell · United States, Argentina, Australia and more3CompletedJul 26, 2021505
NCT03884101Endometrial Neoplasms · United States, Argentina, Australia and more3CompletedOct 2, 2023842
NCT03829332Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more3CompletedMay 19, 2021623
NCT03829319Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Argentina, Australia and more3CompletedAug 11, 2023761
NCT03820986Melanoma · United States, Australia, Austria and more3CompletedJan 18, 2023674
NCT03797326Triple Negative Breast Neoplasms · United States, Argentina, Australia and more2CompletedOct 28, 2024611
NCT03776136Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedOct 11, 2023103
NCT03516981Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Canada and more2CompletedJun 13, 2025245
NCT02861573Metastatic Castration-Resistant Prostate Cancer2Active, not recruitingOct 22, 20271,200

How it is read

Names in the registry

  • “Lenvatinib”, 72 entries
  • “lenvatinib”, 7 entries
  • “E7080”, 6 entries
  • “HOPE”, 2 entries
  • “E7080 capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.